---
schema_version: "secwatch.filing_event.v1"
accession: "0001390478-23-000013"
form_type: "8-K"
ticker: "SLS"
cik: "0001390478"
company_name: "SELLAS Life Sciences Group, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T03:50:26.426626+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# SELLAS reports Q1 net loss $11.1M; GFH009 Phase 1 complete in AML, Phase 2a to start

## Summary
- Net loss $11.1M ($0.47/share) vs $16.7M ($1.05/share) in Q1 2022; cash $23.9M at March 31.
- Phase 1 of GFH009 in AML completed; 94% of patients alive, durable remission >6 months; Phase 2a starting Q2.
- Phase 3 REGAL study of GPS in AML on track for interim analysis late 2023/early 2024; IDMC OK.
- 3D Medicines to trigger $13M milestone payments by Q3 2023 via REGAL participation in China.
- No licensing revenue in Q1 2023 (vs $1M in Q1 2022); R&D expenses rose to $7.2M.

## SEC filing metadata
- accession: 0001390478-23-000013
- form_type: 8-K
- ticker: SLS
- cik: 0001390478
- company_name: SELLAS Life Sciences Group, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000139047823000013/0001390478-23-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1390478/000139047823000013/sls-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001390478-23-000013
- JSON: https://secwatch.observer/filing/0001390478-23-000013.json
- Plain text: https://secwatch.observer/filing/0001390478-23-000013.txt

## Key facts
- Earnings Releases
  SELLAS Life Sciences Group, Inc. reported financial results for the quarter ended March 31, 2023.
  - Period: the quarter ended March 31, 2023
  - Result: reported results
  source text: On May 11, 2023, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended March 31, 2023 and providing a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1390478/000139047823000013/0001390478-23-000013-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.